Skip to main content

Table 4 Cox proportional hazards model with CTC KIN

From: Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients

 

PFS

OS

Hazard ratio

95% CI

P

Hazard ratio

95% CI

P

CTC KIN

 CTCBL- to CTC1C-

1.00

  

1.00

  

 CTCBL+ to CTC1C-

1.01

0.62–1.64

0.981

1.68

0.85–3.32

0.135

 CTCBL+ to CTC1C+

2.17

1.39–3.37

< 0.001

5.58

3.06–10.15

< 0.001

 CTCBL- to CTC1C+

2.17

0.91–5.14

0.079

2.56

0.76–8.00

0.134

Age at inclusion

 Per year

0.99

0.98–1.00

0.333

0.99

0.97–1.01

0.284

Number of metastatic sites

 One site

1.00

  

1.00

  

 Multiple sites

0.94

0.98–1.01

0.832

0.59

0.24–1.48

0.260

Site of metastasis

 Bone

1.00

  

1.00

  

 Visceral/local

1.10

0.59–2.04

0.768

2.12

0.82–5.49

0.124

 Both

1.27

0.68–2.37

0.449

3.35

1.27–8.82

0.014

Line of therapy

 1

1.00

  

1.00

  

 2

1.66

1.00–2.75

0.049

2.01

1.02–3.99

0.045

 ≥ 3

2.49

1.58–3.94

< 0.001

2.49

1.32–4.65

0.004

Molecular Subtypes

 HR+/HER2-

1.00

  

1.00

  

 HER2+

1.34

0.81–2.19

0.252

1.37

0.64–2.91

0.418

 TNBC

2.58

1.53–4.35

< 0.001

3.92

2.11–7.30

< 0.001

  1. Bold P values indicate statistical significance.
  2. HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us